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Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy
morbidity in the presence of circulating antiphospholipid antibodies (aPL). Different pathogenic mechanisms for aPL-
mediated pregnancy failure have been proposed. In particular a direct effect of aPL on both maternal and fetal side of the
placental tissue has been reported, since their reactivity with b2-glycoprotein I (b2GPI) makes them adhere to trophoblast
and human endometrial endothelial cell (HEEC) membranes. b2GPI can be recognized by aPL that, once bound, interfere
with both trophoblast functions and with the HEEC differentiation. APS patients can be successfully treated with Low
Molecular Weight Heparin (LMWH). Recent reports suggest that LMWH acts through mechanisms alternative to its well
known anticoagulant effect, because of its ability to bind b2GPI. In our previous studies, we showed that LMWH is able to
reduce the aPL binding to trophoblasts and restore cell invasiveness and differentiation. So far, however, no study has
described its effects on endometrial angiogenesis. The aim of our research was to evaluate whether two LMWHs,
tinzaparin and enoxaparin, have an effect on the aPL-inhibited endometrial angiogenesis. This prompted us to investigate:
(i) in vitro HEEC angiogenesis through a Matrigel assay; (ii) VEGF secretion by ELISA; (iii) matrix metalloproteinase-2 (MMP-2)
activity by gelatin zymography; (iv) Nuclear Factor-kB (NF-kB) DNA binding activity by colorimetric assay; (v) STAT-3
activation by a sandwich-ELISA kit. Furthermore, using an in vivo murine model we investigated the LMWHs effects on
angiogenesis. We demonstrated that the addition of LMWHs prevents aPL-inhibited HEEC angiogenesis, both in vitro and
in vivo, and is able to restore the aPL inhibited NF-kB and/or STAT-3 activity, the VEGF secretion and the MMPs
activity. The demonstration of a beneficial role for LMWHs on the aPL-inhibited HEEC angiogenesis might provide
additional mechanisms whereby this treatment protects early pregnancy in APS.
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Introduction
‘‘Obstetric’’ Antiphospholipid Syndrome (APS) refers to preg-
nancy morbidity occurring in patients with persistent antiphos-
pholipid antibodies (aPL) [1]. Obstetric criteria used to define APS
are: fetal loss after 10 weeks’ gestation, three or more early
miscarriages (unexplained consecutive embryonic losses before the
10th week of gestation), preeclampsia or features of placental
insufficiency, associated with the premature birth of a morpho-
logically normal neonate before the 34th week of gestation
[2,3,4,5]. Thrombosis in the placental vasculature was initially
thought to be the main cause of adverse pregnancy outcome in the
syndrome [4]. However, the heterogeneity of histological lesions in
APS placentas suggested that intraplacental thrombosis was
unlikely to be responsible for all of the aPL-associated poor
obstetric outcomes [6,7]. Whereas, a direct effect of aPL on
trophoblast cells has been demonstrated through in vitro and
animal studies [6,7,8,9,10,11]. Indeed (i) the demonstration of the
expression of b2-glycoprotein I (b2GPI) on trophoblast cell
membranes; (ii) the aPL ability to bind trophoblast monolayers
in vitro and to negatively affect trophoblast cell functions; (iii) the
raised complement activation and the increased secretion of
Tumor Necrosis Factor (TNF)-a and chemokines observed in in
vivo murine models of APS, all provided important insights into the
pathophysiology of pregnancy morbidity in APS [8,9,10,11].
Our recent studies also demonstrated aPL’s ability to affect the
maternal side of the placenta by directly binding human
endometrial endothelial cells (HEEC) [12]. As a consequence,
aPL induced a significant decrease in both number and total
length of capillary structures formed by HEEC in an in vitro
Matrigel assay [12]. We confirmed this inhibitory effect in vivo
through a murine model [12]. These observations indicate that
aPL act through multiple pathogenic mechanisms, such as
decreased trophoblast invasion and impaired HEEC differentia-
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tation and explain APS pregnancy complications.
Low molecular weight heparins (LMWHs) are widely used in
the management of APS patients [13,14]. Consistent with the
initial aetiological thrombotic theory, this therapy focused on
preventing thrombosis. However, the presence of alternative
mechanisms of placental damage in APS and the success of
heparin treatment on pregnancy outcome stimulated interest on
the drug’s mechanism of action. Accordingly, the protective effects
of heparin have been related to its ability to prevent the binding of
aPL to trophoblast cell membranes and to reduce the local aPL-
induced complement activation at various points in the classical,
alternative and terminal pathways [6,7,15,16,17].
Given these observations, the objective of our study was to
evaluate whether two different LMWHs, tinzaparin and enoxa-
parin, have an effect on the aPL-inhibited endometrial angiogenesis
both in vitro and in vivo. An additional aim was to investigate the
regulationofintracellularHEEC-signallingmechanismsinpresence
of aPL with or without increasing doses of these LMWHs. Any
demonstration of the beneficial role of LMWHs on the aPL-
inhibitedHEEC angiogenesismightprovide additional mechanisms
by which this treatment protects early pregnancy in APS patients.
Materials and Methods
Antibody preparation
Polyclonal aPL were isolated from patients with APS, diagnosed
according to the revised Sapporo criteria [5]. All patients provided
informed consent for participating in the study. The study was
approved by the human investigation committee of the Universita `
Cattolica del Sacro Cuore (Rome, Italy).
IgGs were purified by affinity chromatography using protein G-
Sepharose chromatography columns (Amersham Biosciences, GE
Healthcare, CH) [11]. The final protein IgG concentration was
evaluated by nephelometry and the specific reactivity with CL and
b2GPI-coated plates was confirmed as previously described [18].
Sterile-filtered IgG fractions were determined to be free of
endotoxin contamination by the limulus amoebocyte lysate assay
(E-Toxate, Sigma Chemical Co., St. Louis, MO; sample sensitivity
,0.03 IU/ml).
Tissue collection
Endometrial tissues were obtained from fertile women (in the
mid secretory phase) undergoing hysterectomy for fibroid uterus or
biopsy (n=seven biopsies per procedure) for benign diseases
(written informed consent was obtained from each patient before
the surgery). The mean age of the patients was 37.4 years, range
30–42 years. The day of the menstrual cycle was determined by
the patients’ menstrual history and was verified through the
histological examination of the endometrium according to Noyes
criteria [19]. Estradiol and progesterone were determined in the
serum to confirm the mid secretory phase. The tissues were placed
in Hank’s balanced salt solution (HBSS) and carried to the
laboratory for HEEC isolation and culture. Each experimental
setup was repeated on at least five occasions using cells obtained
from different patients.
HEEC isolation and purification
The endometrium was minced and incubated in M199/
penicillin/streptomycin containing 0,2% collagenase type II at
37uC for 2 hours (hrs). At the end, all remaining tissue was
dissolved by powerful resuspension, resulting in a homogenous
solution. After centrifugation (1200 rpm for 5 min at room-
temperature), the pellet obtained was resuspended in culture
medium and transferred into a fibronectin-coated culture dish.
After 2–4 hrs, the non-adhered cells were removed and the
adherent cells were cultured in human endometrial microvascular
endothelial cells (hEMVEC) culture medium.
The primary heterogeneous cell population was grown until
near confluence before selection of the endothelial cells using anti-
human CD31 and CD105 coated microbead (Miltenyi Biotec
S.r.l, Italy). In brief, after detachment using trypsin and
centrifugation, the cells were immunolabelled with CD31 and
then CD105 MicroBeads (20 ml per 1610
7 cells) before being
loaded onto a column placed in the magnetic field of a MACS
Separator. The magnetically labeled CD31
+/CD105
+ cells were
retained on the column, whereas, the unlabelled cells passed
through. After removing the column from the magnetic field, the
positive CD31
+/CD105
+ magnetically retained cells were eluted
and taken directly into culture or analyzed for purity by flow
cytometry.
Flow cytometry
Characterization of the isolated HEEC was performed by flow
cytometry. Briefly, aliquots of HEEC were incubated for 15 min at
room-temperature with specific endothelial markers: FITC- or
APC- conjugates monoclonal antibodies (MoAbs) VE-cadherin
and/or KDR (R&D System, Abingdon, UK). Appropriate
fluorochrome-conjugated isotype-matched irrelevant MoAbs were
used as control for background staining. Cells were run through a
flow cytometer (FACSCanto, Becton Dickinson, Mountain View,
CA, USA). A minimum of 10,000 events were collected and
acquired in list mode with the accompanying software (FACS Diva
software, Becton Dickinson; Figure 1). Human Umbilical Vein
Endothelial Cells (HUVEC, American Type Culture Collection,
ATCC, USA) were used as positive control (data not shown).
Figure 1. HEEC characterization. Endometrial samples were
subjected to CD31 and CD105 cell immunomagnetic isolation by
incubation with anti-CD31 and anti-CD105 conjugated-microbeads, and
subsequent loading on a MidiMACS device. Cell viability after
immunoselection exceeded 98% in all cases, as judged by propidium
iodide staining by flow cytometry. Cells recovered were analyzed for the
presence of endothelial markers (Vascular Endothelial Growth Factor
Receptor-2 or KDR and CD 105) by flow cytometry analysis (KDR-PE/
CD105-FITC=97%).
doi:10.1371/journal.pone.0029660.g001
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Endothelial cell differentiation into capillary-like tube structures
was monitored by BD Biocoat angiogenesis system (BD Bioscienc-
es).HEEC wereseededon Matrigel-coated plates(2610
4 cell/wells)
in endothelial cell differentiation culture medium (EBM-2) MV
Single Quots (Lonza, Milan, Italy) containing aPL (50 mg/ml) in
combinationwith either tinzaparin (0.1–10 IU/ml, innohepH, LEO
Pharma A/S, Ballerup, Denmark) or enoxaparin (0.1–10 IU/ml,
Clexane, Sanofi SpA, Milan, Italy) and incubated for 8–12 hrs at
37uC, ina 5%CO2 atmosphere. Suramin40 mM (Calbiochem, San
Diego, CA, USA) was used as a negative control.
Following incubation, the plates were washed twice with HBSS
and the tube formation was observed using an inverted phase
optical microscope (Olympus, IX50, Milan, Italy). Images were
acquired with a digital camera (Nikon, Tokyo, Japan) and
quantified by Photoshop software (San Jose, CA, USA) measuring
the number and the total length of the tubules within each well.
Measurement of Nuclear Factor-kB (NF-kB) DNA binding
activity
DNA binding activity of NF-kB was measured with a sensitive
multiwell colorimetric assay (Transcription Factor Assay kit;
Millipore, Temecula, USA). In short, HEEC cultured in
endothelial cell differentiation medium (EBM-2) MV Single Quots
were scraped and centrifuged for 10 minutes at 1,500 rpm. The
pellet was resuspended in 100 ml of lysis buffer and the lysate was
centrifuged for 20 minutes at 15,000 rpm. The supernatant
represented the total protein extract and the remaining pellet
contained the nuclear portion of cell lysate. The nuclear pellet was
resuspended in ice-cold nuclear extraction buffer for 30–
60 minutes at 4uC and then centrifuged at 16,000 rpm for
5 minutes. The nuclear extracts in the supernatant (5 mg/5 ml)
from each sample were incubated in 96-well plates coated as
follows: with NF-kB consensus double-stranded oligonucleotide
sequence (59-AGTTGAGGGGACTTTCCCAGGC-39) for 1 hr,
then with primary NF-kB antibody (1:500) for 1 hr, subsequently
with peroxidase-conjugated secondary antibody (1:500) for 1 hr,
and finally with peroxidase-conjugated secondary antibody
(1:1000) for 1 hr at room-temperature. After colorimetric reaction,
optical density was read at 450 nm. For competition assays, cell
extracts were incubated with 22-bp double-stranded DNA, either
wild-type or mutated (59- AGTTGAGCTCACTTTCCCAGGC-
39; underline denotes the substitution). Competition experiments
performed with a 100-fold excess of unlabeled KB oligonucleotide
demonstrated the specificity of the DNA binding activity.
Measurement of STAT-3 phosphorylation
STAT-3 phosphorylation in presence of aPL with, or without,
LMWHs was examined using a sandwich-ELISA kit (PathScanH
Phospho-Stat3 (Tyr705) Sandwich ELISA; Cell Signaling Tech-
nology Inc., Danvers, MA, USA) according to the instructions
provided by the manufacturer. Briefly, cells were lysed using ice-
cold lysis buffer and the lysates were further sonicated on ice.
Then, 100 ml of the respective lysates were added to a microplate
well and incubated at 37uC for 2 hrs. After incubation both non
phospho- and phospho- -STAT3 proteins were captured by the
coated antibody. Following extensive washing, a phospho-STAT3
mouse monoclonal antibody was added to detect the captured
phospho-STAT3 protein. HRP-linked anti-mouse antibody was
then used to recognize the bound detection antibody. HRP
substrate, TMB, was added to develop colour. The magnitude of
optical density for this developed colour was proportional to the
quantity of phospho-STAT3 protein (absorbance of each well was
measured at l=450 nm).
Vascular Endothelial Growth Factor (VEGF) secretion
VEGF secretion was determined by a human VEGF colorimetric
ELISA kit (Pierce Endogen, Rockford, USA) according to the
manufacturer’s instructions. Briefly, HEEC were plated in 24-well
plates at 50,000 cells/well in endothelial cell culture medium with
5% FBS containing aPL (50 mg/ml) with or without LMWHs
(tinzaparin or enoxaparin,0.1–1.0 IU/ml)and incubated for 24 hrs
at 37uC and 5% CO2 atmosphere. Culture medium or standard
(50 ml) was added to each well, previously coated with human
monoclonal anti-VEGF antibody. After 2 hrs of incubation, wells
were washed and incubated with an enzyme-linked polyclonal anti-
VEGF antibody. 3,39,5,59-Tetramethyl benzidine substrate solution
(TMB) was added to each well and the colour developed in
proportion to the amount of the VEGF bound in the initial step.
The plate was read on a Titertek Multiscan plus Mk II plate reader
(ICN Flow Laboratories, Irvine, CA, USA) by measuring the
absorbance at a wavelength of 450 nm minus 550 nm.
Matrix Metalloprotease (MMP)-2 activity
MMP-2 levels in the supernatant of HEEC cultures were
measured by gelatine zymography. Samples were electrophoresed
on SDS-polyacrylamide gel containing 0.3% gelatin. Following
electrophoresis, gels were washed 3 times in 2.5% Triton X-100 for
10 min at room-temperature, to remove SDS. After overnight
incubation at 37uC in 50 mM Tris-HCl (pH 7.4, containing 5 mM
CaCl2, 0.15 M NaCl and 0.02% NaN3), gels were stained with
0.5% CoomassieBrilliantBlue for 30 minutes and then destained in
20% methanol and 10% acetic acid. Gelatinolytic activities were
observed as clear bands of digested gelatine on a blue background.
Images were acquired with a digital camera (Nikon, Tokyo, Japan)
and bands were analyzed on the Image Analysis System Gel Doc
200 System (Bio-Rad Laboratoires) by using Quantity One
Quantitation Software (Bio-Rad Laboratoires).
Angiogenesis by Direct In Vivo Assay
Five-week-old CD1 female nude mice obtained from an
outbreed background were purchased from Charles River
Laboratory. The housing and handling of these mice were in
accordance with institutional guidelines and compliant with
national (Ministry of Health, Rome, Italy) and international
regulation (European Community and National Institutes of
Health, Bethesda, MD). All experimental procedures were
approved by the local ethical committee on preclinical studies
(Commissione per la Valutazione Etica di Sperimentazioni
Animali e di Correttezza della Gestione dell’‘‘animal care’’.
Approval ID: HH 13). The mice were allowed to acclimatise to
their new environment for one week. They were housed in
disinfected polycarbonate mouse cages, maintained in a cabinet
with laminar flow at 28uC under controlled artificial lighting
(12 hrs light/12 hrs dark), and given ad libitum access to rodent
chow and water during the study. We performed the experiments
on groups of 10 animals. For direct angiogenesis assay, the direct in
vivo assay (DIVA) kit was used (Trevigen, Inc., Gaithersburg, MD,
USA). Briefly, angioreactors were filled with Matrigel with, or
without, the angiogenic factor (Fibroblast Growth Factor-2, FGF-
2), and polyclonal aPL (50 mg/ml) with, or without, different
concentration of LMWHs. They were incubated at 37uC for 1 hr
to allow gel formation, before subcutaneous implantation into the
dorsal flank of the mice. In each mouse, two angioreactors were
implanted: the positive control (angioreactor coated with FGF-2)
in the left flank and the angioreactor with FGF-2 and aPL (50 mg/
ml) with or without tinzaparin in the right flank. At the end of the
experiment, the angioreactors were collected and the new vessel
formation was determined by FITC-lectin staining. After staining,
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multiwell plates using a spectrofluorimeter reader (Twinkle LB
970, Berthold Technologies. excitation, 485 nm; emission,
510 nm). The mean relative fluorescence 6 SE was determined
for five replicate assays.
Statistical Analyses
The results are expressed as the means 6 standard error (SE).
One way analysis of variance (ANOVA) was used to determine
significant differences among groups. When appropriate, a post-
hoc test (Bonferroni test) was used to determine the significance of
difference between pairs of means. Statistical significance was
accepted at P,0.05.
Results
HEEC characterization
Five different endometrial samples were incubated with anti-
CD31 and anti-CD105 conjugated-microbeads, and subsequent
loaded on MidiMACS device. Cell viability after immunoselection
exceeded 98% in all cases, as judged by propidium iodide staining
by flow cytometry.
Cells recovered were analyzed for the expression of endothelial
markers (VEGF Receptor-2 or KDR and CD105 by flow
cytometry analysis (KDR-PE/CD105-FITC=95.71.%).
In vitro angiogenesis
The number (Figure 2A) and total length (Figure 2B) of the
tubules were examined by microscopy. We observed that the
addition of tinzaparin and enoxaparin significantly abrogated the
aPL-mediated inhibition of tube formation. (f:P ,0.05 compared
with CTR; *:P ,0.05 compared with aPL). We reported the
significant difference between tinzaparin and enoxaparin effect (s:
P,0.05 enoxaparin vs tinzaparin).
Intracellular mechanisms regulating VEGF expression in
HEEC. Effects of aPL and LMWHs on NF-kB and STAT-3
activation
Figure 3A summarizes NF-kB and STAT-3 signalling
pathways, two intracellular mechanisms independently activated
during HEEC angiogenesis [20,21,22,23,24]. The effects of
LMWHs on aPL inhibited NFkB binding activity and activation
of STAT-3 in presence of aPL with, or without, LMWHs were
Figure 2. In vitro angiogenesis assay. To evaluate the effects of tinzaparin or enoxaparin on aPL-inhibited angiogenesis we used an in vitro assay
of human endometrial endothelial cells (HEEC) capable of forming tube-like structures in response to the extracellular matrix protein, Matrigel, in
endothelial cell culture medium (EBM-2) MV Single Quots. Cells were seeded in matrigel coated plates and examined for tube formation
microscopically. The figure shows the quantitative analysis of number (A) and total length (B) of tube-like structures after treatment with aPL (50 mg/
ml) with or without tinzaparin or enoxaparin (0.1–10 IU/ml). Results are means 6 SE of five experiments and expressed as % of control (CTR=100).
(CTR: untreated cells; f:P ,0.05 compared with CTR; *: P,0.05 compared with aPL; s:P ,0.05 enoxaparin vs tinzaparin).
doi:10.1371/journal.pone.0029660.g002
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of NF-kB binding activity was stopped by the presence of
tinzaparin or enoxaparin (0.1–1.0 IU/ml) (Figure 3B; f:
P,0.01 compared with CTR; *: P,0.001 compared with aPL-
treatment). (ii) aPL (50 mg/ml) inhibited STAT-3 phosphorylation
and the addition of tinzaparin (0.1–1.0 IU/ml) to the cultures
prevented the aPL-mediated inhibition (Figure 3C; f:P ,0.05
compared with CTR; *: P,0.05 compared with aPL treatment),
whereas no effect was observed after enoxaparin treatment (data
not shown)).
VEGF and MMP-2 secretion
As shown in Figure 4, aPL (50 mg/ml) reduced VEGF
production and such inhibition was blocked by the addition of
tinzaparin (A) or enoxaparin (B) at a dose of 0.1 and 1.0 IU/ml (f:
P,0.05 compared with CTR; *: P,0.01 versus aPL treatment).
Moreover, addition of tinzaparin or enoxaparin HEEC (0.1–
1.0 IU/ml) significantly blocked the aPL-inhibited pro- and
active-MMP-2 secretion in HEEC culture supernatant, as
evaluated by gelatine zymography (Figure 5; f:P ,0.05
compared with CTR; *: P,0.05 versus aPL treatment).
In vivo angiogenesis
In the presence of tinzaparin or enoxaparin, aPL-inoculated
mice revealed a significant increase in new vessel formation
compared to the group of mice inoculated with aPL alone
(Figure 6; f:P ,0.05 compared with CTR; *: P,0.05 compared
with aPL treatment). Results are means 6 SE (n=5 mice per
Figure 3. Intracellular mechanisms regulating VEGF expression in HEEC. Effects of aPL and LMWHs on NF-kB and STAT-3 activation.
A. VEGF is a well-known factor able to promote endothelial cell proliferation and new vessel formation. Several intracellular mechanisms regulate
VEGF expression in HEEC including NF-kB and STAT-3. The figure illustrates these two signalling pathways whose activation increases VEGF
expression. NF-kB activity is regulated by the interaction with the inhibitory IkB protein. Upon activation, IkB is phosphorylated and degraded, thus
allowing NF-kB to translocate into the nucleus and bind to VEGF promoter region, upregulating the expression of this proangiogenic factor by HEEC.
Moreover STAT-3 is a member of JAK-STAT signalling pathway. It is a latent transcription factor which is activated by phosphorylation. Activated
STAT-3 protein induces its nuclear translocation and favours VEGF expression. B. NF-kB activation in the presence of aPL alone or with tinzaparin or
enoxaparin after 4 hrs of treatment in differentiation culture medium. aPL reduced NF-kB activation while tinzaparin or enoxaparin were able to
restore the NF-kB DNA binding activity. The values are O.D. mean 6 SE of three different experiments. CTR: untreated cells; T: tinzaparin; E:
enoxaparin; O.D.: Optical Density; f:P ,0.01 compared with CTR; *: P,0.001 compared with aPL-treatment. C. Effects of aPL on STAT-3
phosphorylation in the presence of tinzaparin after 4 hrs of treatment in differentiation culture medium. aPL reduced STAT-3 activation while
tinzaparin was able to restore the STAT-3 phosphorylation. Values are O.D. means 6 SE of three different experiments. CTR: untreated cells; T:
tinzaparin; O.D.: Optical Density; f:P ,0.05 compared with CTR; *: P,0.05 compared with aPL treatment.
doi:10.1371/journal.pone.0029660.g003
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samples were collected after 24 hrs of aPL (50 mg/ml) and tinzaparin (A) or enoxaparin (B) (0.1–1.0 IU/ml) treatment for VEGF measurement. Results
are mean 6 SE of four independent experiments and are expressed O.D. (Optical Density). CTR: untreated cells; T: tinzaparin; E: enoxaparin; O.D.:
Optical Density; I.U.: International Units; f:P ,0.05 compared with CTR; *: P,0.01 versus aPL treatment.
doi:10.1371/journal.pone.0029660.g004
Figure 5. MMP-2 activity evaluation by gelatine zymography. Influence of aPL (50 mg/ml) with or without tinzaparin or enoxaparin treatment
on pro-MMP-2 and active MMP-2 gelatinolytic capacity in the supernatant of HEEC. Results are means 6 SE from five experiments and expressed as %
of control (CTR). CTR: untreated cells; O.D.: Optical Density; I.U.: International Units; f:P ,0.05 compared with CTR; *: P,0.05 versus aPL treatment.
doi:10.1371/journal.pone.0029660.g005
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confirmed the LMWHs ability to abrogate the aPL–mediated
inhibition of angiogenesis.
Discussion
In the present study we demonstrated that two different
LMWHs, enoxaparin and tinzaparin, are able to prevent the
aPL-mediated inhibition of HEEC angiogenesis both in vitro and in
vivo. The LMWHs positive effects involve the up-regulation of
signalling pathways and transcriptional factors which are down-
regulated in the presence of aPL.
Antiphospholipid antibodies represent a heterogenous group of
autoantibodies which do not recognize phospholipids (PL) directly,
but via a phospholipid-binding protein: b2GPI. The latter is a
highly glycosylated 50-kDa protein consisting of 326 amino acids
organized in five domains [25,26,27]. Each domain consists of 60
amino acids, with the exception of domain V, which consists of 82
amino acids forming a hydrophobic loop [26,27]. This specific
structure of domain V is responsible for the binding properties of
b2GPI to anionic PL [26,27]. It has been reported that LWMH
recognizes a positively charged site within the V domain of b2GPI
that is also the same site that interacts with PL [28]. Thus heparin
functions as a competitive inhibitor for the PL-binding site and
presumably, through this mechanism, ultimately interferes with
the binding of aPL to targeted cells [28]. Accordingly, in previous
investigations we demonstrated that LMWH reduces the aPL-
binding to trophoblast cells and restores in vitro placental
invasiveness and differentiation [15,17,29]. Therefore, we drew
the conclusion that heparin, by preventing the binding of b2GPI
to negatively charged PL, is able to prevent the deposition of the
anti-b2GPI antibodies in tissues and -as a consequence- protect
trophoblast PL from the aPL mediated effects during early
pregnancy [8,29].
Subsequent studies, performed on murine models of APS,
demonstrated that treatment with heparin prevents complement
activation in vivo and protects mice from pregnancy complications
induced by aPL [16,30], possibly through its anti-inflammatory
action, being able to prevent leukocyte influx/attachment to
activated endothelium and to inhibit proinflammatory cytokine
secretion [30,31]. Altogether these findings prove the multiple
protective effects of LMWH against aPL-induced placental
damage, which are in addition to its well-known anticoagulant
properties. However, to date, it was not known whether LMWHs
have a possible role on the maternal/endometrial side of human
placenta. With this in mind, in our study we evaluated whether
two different LMWHs, tinzaparin and enoxaparin, might affect
the aPL-inhibitory action on HEEC by modulating some of the
most known intracellular pathways that regulate the process of
angiogenesis.
During angiogenesis, a coordinated series of steps allows HEEC
to invade, migrate and proliferate into the underlying interstitial
matrix and form a new capillary structure [20,21]. A key player in
this process is represented by VEGF whose function is to promote
the survival, migration and differentiation of endothelial cells, as
well as to mediate vascular permeability [32,33]. Two of the most
important intracellular pathways, which finely control VEGF
expression and are activated independently during angiogenesis,
are NF-kB and STAT-3 [20,21,22,23]. NF-kB is a critical
transcriptional factor recognizing multiple regulatory elements in
the VEGF promoter region. NF-kB activity is regulated by the
interaction with inhibitory IkB protein. Upon activation, IkBi s
phosphorylated and degraded, thus allowing NF-kB to translocate
to the nucleus and bind with VEGF promoter region, upregulating
the VEGF expression in HEEC. In turn, VEGF stimulates the
expression and activity of MMP-2, a proteolytic enzyme degrading
the basement membrane [20,21,22,23,24,34]. On the other hand,
STAT-3 is a latent transcription factor, member of the
Figure 6. In vivo angiogenesis assay. Effects of aPL with or without LMWHs on angiogenesis process in vivo. Endothelial cells in the angioreactors
were incubated with FITC-lectin, recovered and analyzed for FITC-lectin by fluorescence spectrometry. The analysis demonstrated reduced
fluorescence (45%) in angioreactors containing aPL (50 mg/ml) compared with the positive controls. Tinzaparin or enoxaparin were able to
completely reverse this angiogenesis inhibition. Results are means 6 SE (n=5 mice per group) from three independent experiments and expressed
as RFU (Relative Fluorescent Units), % of control. CTR+: positive control; T: tinzaparin; E: enoxaparin; I.U.: International Units; f:P ,0.05 compared with
CTR; *: P,0.05 compared with aPL treatment.
doi:10.1371/journal.pone.0029660.g006
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activation translocates to the nucleus and favours VEGF
expression [24]. Consistent with our previous results, we observed
that aPL are able to decrease HEEC angiogenic functions in vitro
and in vivo. Such inhibition is well correlated with an impaired NF-
kB activation, VEGF secretion and MMP-2 activity. In addition
we showed that LMWH treatment prevented the aPL-mediated
inhibition of HEEC angiogenesis both in vitro and in vivo and we
suggest the increased activation of NF-kB and/or STAT-3 as a
possible mechanism by which tinzaparin and enoxaparin might
restore HEEC angiogenic capacity. The angiogenic effect was
observed starting from a dose as low as 0.1 I.U/ml. We can
speculate that this action might be due to the peculiarity of our
model in which the drug is directly delivered to the cell surface.
Growing evidence suggests that failure in the development of a
functional placental vasculature, due to an imbalance between
placental pro-angiogenic factors (such as VEGF) and anti-
angiogenic factors, leads to defective placentation and thus to
severe obstetrical consequences such as recurrent pregnancy loss
and preeclampsia [33,35,36]. Accordingly, we have demonstrated
that aPL reduce VEGF secretion by HEEC and that LMWH
prevents this inhibitory effect, suggesting a further mechanism by
which LMWH protect placental tissue from aPL negative actions.
Several studies have described the inhibitory effect of LMWHs
on angiogenesis both in vitro and in vivo, suggesting that this action
is not exclusively related to their anticoagulant function, but
perhaps to their interference with the activity of angiogenic growth
factors or proteolytic enzymes, to the binding to ECM compo-
nents, or to the potential effects on pericytes [37,38,39]. In
preliminary experiments, we confirmed these reports, observing
that both tinzaparin and enoxaparin reduced, in a dose-dependent
manner, HEEC angiogenesis both in vitro and in vivo (data not
shown). However, the purpose of our study was not to evaluate the
role of LMWHs on endometrial angiogenesis, but to examine
whether treatment with increasing doses of LMWHs might
interfere with the aPL-inhibited HEEC angiogenic behaviour.
Antiphospholipid antibodies have been shown to recognize b2GPI
expressed on endothelial cells and, once bound, to impair cellular
functions [40,41]. Our data prove that LMWHs are able to
antagonise the aPL-mediated effects on HEEC and suggest that
such action may be due to the LMWHs’ ability to disrupt the
interaction of b2GPI with PL on the surface of HEEC.
A noteworthy aspect of our results is that primarily tinzaparin
improves aPL-inhibited in vitro angiogenesis and STAT-3 activity.
It is difficult to explain this difference and caution is necessary in
extrapolating our obtained results. Indeed we used doses of
tinzaparin and enoxaparin measured in international units, which
are established according to their anti-Xa activity. However, this
activity is independent of the biological effect examined in our
study. Thus, using the same dose for both drugs does not mean
that one drug is necessarily more effective, since it is not known
exactly which component of the LMWH causes the effect nor its
concentration within the molecule. Alternatively one possible
explanation of this different behaviour might be that, although
these LMWHs share a similar mechanism of action, they must be
considered as distinct compounds whose differences can be
explained by comparing methods of preparations, molecular
structures and electrostatic charge [42,43]. Considering these
differences, it might also be expected that the different biological
activity of tinzaparin and enoxaparin, on aPL-mediated inhibition
of angiogenesis and on the intracellular mechanisms regulating this
process, depend on their unique polysaccharide chain length
spectrums and the total amount of negatively charged polyanions.
In conclusion, we previously reported that aPL contribute to
defective placentation in APS patients not only by impairing
trophoblast cells functions, but also by decreasing HEEC angiogen-
esis [44,12]. We also demonstrated that LMWH is able to reduce the
aPL antibody binding to trophoblast cells and to restore in vitro
placental invasiveness and differentiation [8,12,15]. We now show
that two LMWHs, tinzaparin and enoxaparin, are able to block aPL-
inhibition of HEEC angiogenic behaviour and propose several
pathways of action. These observations support the beneficial role of
LMWHs, not only on the fetal side of the placenta (trophoblast cells),
but also on the maternal one (endometrial endothelial cells), hence
supporting the presence of multiple mechanisms through which
LMWHs may protect APS pregnancy in the early stages.
In clinical practice several strategies have been proposed to
improve the outcome of APS pregnancy, including combinations
of aspirin, UFH and/or LMWH. However, few well designed
trials have been carried out, thus there is no clear evidence about
which treatment regimen should be preferred and whether UFH
and LMWH have a comparable efficacy. LMWH preparations
differ in their methods of production, molecular weight, half-life
and anticoagulant activity. Notably, the optimal LMWH has also
to be defined. Although LMWHs represent a treatment for
prevention of pregnancy complications in APS, little is known
about the cellular mechanisms by which heparin exerts its effect on
placental tissue. Our investigations provide an important mech-
anism by which LMWHs are able to prevent the aPL mediated
placental damage. Additional in vitro and in vivo studies are needed
to confirm our preliminary results demonstrating the predominant
tinzaparin effect in restoring in vitro angiogenesis. The outcome of
these studies should support large randomized placebo-controlled
trials assessing the efficacy of LMWH preparations in the
prevention of pregnancy complications associated with APS.
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